Exon 19 Deletions

Amivantamab-vmjw with carboplatin and pemetrexed is approved by the USFDA for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations

On September 19, 2024, the Food and Drug Administration sanctioned amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in conjunction with carboplatin and pemetrexed for adult patients diagnosed with ...
exon-19-deletions

Scan the code

Tag: Exon 19 Deletions

Home / Exon 19 Deletions

Categories

Amivantamab-vmjw with carboplatin and pemetrexed is approved by the USFDA for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations

Information

Treatment

China (Beijing)

Romania

India (Hyderabad)

Cambodia

China (Shanghai)

Hong Kong